In this episode, Sonal Kumar, MD, MPH, discusses key findings from primary biliary cholangitis (PBC) studies presented at AASLD 2024, including:

• ELATIVE, a phase III trial of elafibranor for PBC
• RESPONSE, a phase III trial of seladelpar for PBC
• ASSURE, another phase III trial of seladelpar for PBC

Presenter:
Sonal Kumar, MD, MPH
Director, Clinical Gastroenterology and Hepatology
Assistant Professor of Medicine
Weill Cornell Medical College
New York, New York

Link to full program:
https://bit.ly/41tvSDu

Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

Clinical gaps in the treatment of pruritus in primary biliary cholangitis (PBC) remain. In this episode, taken from a recent symposium, Marlyn J. Mayo, MD; Stuart C. Gordon, MD; and Pam Rivard, RN, a person living with PBC, discuss emerging therapies currently in clinical trials for the management of this disease that can dramatically affect patients’ quality of life.

Listen as they discuss:

• Gaps in current management
• Patient perspectives: why we should not dismiss itching as an underlying psychologic problem
• PPAR agonists and how they affect pruritus
• BEZURSO and FITCH
• ELATIVE
• ENHANCE and RESPONSE
• IBATs (inhibitors of bile acid transport)
• GLIMMER
• Common questions

Presenters:

Marlyn J. Mayo, MD
Professor of Internal Medicine
Division of Digestive & Liver Diseases
UT Southwestern Medical Center
Dallas, Texas

Stuart C. Gordon, MD
Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health
Detroit, Michigan

Pam Rivard, RN
Person living with PBC

Link to full program:
https://bit.ly/3Dnfb2E

Although there is currently no FDA-approved treatment for pruritus in primary biliary cholangitis (PBC), symptoms can be mitigated with nonpharmacologic or pharmacologic agents. In this episode, Marlyn J. Mayo, MD; Stuart C. Gordon, MD; and Pam Rivard, RN, a person living with PBC, discuss the clinical management of pruritus in PBC, including:

• Pruritus assessment tools
• Optimal use of tools, including frequency of assessment
• Current management of pruritus
• Nonpharmacologic interventions
• Pharmacologic agents
• Strategies to optimize assessment and management of pruritus
• Collaborative care
• Development of a treatment plan
• Ongoing assessment and adjustment of therapy
• Resources and support for patients

Presenters:

Marlyn J. Mayo, MD
Professor of Internal Medicine
Division of Digestive & Liver Diseases
UT Southwestern Medical Center
Dallas, Texas

Stuart C. Gordon, MD
Professor of Medicine
Wayne State University School of Medicine
Director, Division of Hepatology
Henry Ford Health
Detroit, Michigan

Pam Rivard, RN
Person living with PBC

Link to full program:
https://bit.ly/3Dnfb2E